Current Medical Research and Opinion · 2018 · 11 citations · 20 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDiabetologyPharmacovigilanceDiabetes ControlDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyGlycemic ControlGlycemic MonitoringCombination TherapyGlycated Hemoglobin MonitoringHemoglobin LevelsObservational Study EvaluationTherapy TolerabilityType 2 Diabetes Mellitus TreatmentType 2 Diabetes PharmacotherapyType 2 Diabetes Treatment
AIMS: To assess the effectiveness and safety of vildagliptin/metformin initial combination therapy in drug-naïve patients with type 2 diabetes mellitus (T2DM). METHODS: INITIAL was a 24-week prospective, observational study in T2DM patients with glycated hemoglobin (HbA1c) ≥ 7.5%, and prescribed vildagliptin/metformin as initial combination therapy. The primary endpoint was change in HbA1c from baseline to week 24. Key secondary endpoints were HbA1c change from baseline to week 12, proportion of patients achieving HbA1c ≤7.0%, change in body weight at 12 and 24 weeks, change in HbA1c by sub-groups (baseline HbA1c, age, body mass index [BMI], dosage strength, co-morbidities) from baseline to week 24, and safety. RESULTS: , respectively. Cardiovascular risk factors present at baseline were dyslipidemia (30.1%), hypertension (29.7%), and obesity (20.9%). The mean reductions in HbA1c from baseline to week 12 (-1.6 ± 1.59%) and 24 (-1.9 ± 1.70%) were statistically significant (p < .001). At 24 weeks, 39.6% of patients achieved HbA1c ≤ 7.0%, and the mean body weight reduction was -1.1 ± 2.62 kg. HbA1c reductions were consistently seen from baseline to weeks 12 and 24 in the various sub-groups. Overall, 48 (9.0%) patients reported adverse events, including one hypoglycemic episode. There were no serious adverse events or deaths. CONCLUSIONS: Overall, in a relatively young drug-naïve T2DM Asian study population with high baseline HbA1c and often associated with cardiovascular risk factors, vildagliptin/metformin combination therapy was associated with significant and clinically relevant HbA1c reduction from baseline. This effect was seen at week 12, was maintained over 24 weeks, and was accompanied by good tolerability.
20
International Diabetes Federation 2017
Ann M. Carracher, Payal H. Marathe, Kelly L. Close · Journal of Diabetes · 2018 · 13.6K citations · Full text
Medicine, Endocrinology, Diabetology +11
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel et al. · New England Journal of Medicine · 2008 · 7.8K citations · Full text
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care · 2014 · 3.1K citations · Full text
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay et al. · Endocrine Practice · 2016 · 875 citations